Back

Usefulness of fibroblast growth factor 23 and soluble suppression of tumorigenicity 2 as predictors of poor outcome in heart failure with preserved ejection fraction

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Exploring biomarkers in heart failure Biomarkers ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Clotilde Roy

Jolimont Lobbes Hospital, La Louviere (Belgium)

9 More presentations in this session

Presentation thumbnail
Prognostic impacts of soluble form of basigin in patients with chronic heart failure -from a prospective large clinical trial with 1,147 patients-
Associate Professor K. Satoh (Sendai, JP)
Abstract Slides Video
Presentation thumbnail
Mid regional atrial natriuretic peptide is an independent predictor of peak pulmonary capillary wedge pressure in patients with heart failure with preserved ejection fraction
Doctor S. Nanayakkara (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Association of NGAL and AHEAD score for two-year prognosis in chronic heart failure patients (FAR NHL registry)
Doctor K. Labr (Brno, CZ)
Abstract Slides Video
Presentation thumbnail
Machine learning facilitates selecting a group of metabolites non-inferior to BNP for the diagnosis of chronic heart failure
Doctor M. Marcinkiewicz-Siemion (Bialystok, PL)
Abstract Slides Video
Presentation thumbnail
Optimizing patient selection in heart failure trials: the role of NT-proBNP
Doctor G. Savarese (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Exploring biomarkers in heart failure

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
The role of a multimarker panel in the diagnosis and prognosis of patients with acute heart failure
thumbnail
Congress Presentation
Novel biomarkers reveal distinct biological phenotypes in heart failure with preserved vs reduced ejection fraction
thumbnail
Congress Presentation
Growth differentiation factor 15 and absorption loss as new biomarkers of heart failure decompensation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources